Ana Velázquez Mañana, shared a post on X, about a recent article by John Heymach et al. published in NEJM, adding:
“Lung Cancer Clinical Trials at AACR25!
Zongertinib in pretreated HER2 mutant NSCLC: Beamion LUNG-1
– ORR 71% (7% CR) with mDOR 14.1 mo
– mPFS 12.4 mo (95% CI, 8.2 to NR)
– Intracranial ORR 41%
– Pretx with HER2 ADC (cohort 5; n=31) ORR 48%
– Improved AE profile compared to prior TKIs and NO ILD reported.
– Active also in non-TKD mut.
By Dr. John Heymach, MD Anderson Cancer
Publication in NEJM.”
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
Authors: John Heymach et al.
More posts featuring Ana Velázquez Mañana on OncoDaily.
